Author:
García Domínguez Miguel,Anaya Enríquez Nancy,Luque-Vega Lynnete,Canizales Muñoz Saúl,Flores Rosalino,Tostado Morales Edgardo,Torres Cynthia G.,Melchor Vianey,Quibrera José,León-Ramírez Ángel Rito,Velázquez-Rios Carlos,Carreón-Guerrero Juan Manuel,Llausás-Magaña Eduardo
Abstract
Objective: To evaluate the differences and similarities in clinical picture, laboratory findings and outcomes between children’s with Kawasaki Disease (KD) versus multisystem inflammatory syndrome (MIS-C).
Methods: We conducted a retrospective, comparative study from children with Kawasaki Disease (KD) hospitalized in Sinaloa Pediatric Hospital from January 1, 2004, to March 31, 2020, and patients with multisystem inflammatory syndrome (MIS-C) according with World Health Organization (WHO) case definition criteria between May 1, 2020 and May 31, 2021. Demographic characteristics, epidemiological data, clinical features, laboratory findings, type of treatment and clinical outcomes were compared among both groups.
Results: Eighty-one patients were included (62 patients with KD and 19 with MIS-C). several clinical and laboratory differences were found among these two entities. Median age was lower in KD vs. MIS-C (25 vs 79 months). Mucocutaneous features (93.5 vs. 63.2%): Oral changes (83.9 vs. 63.2%) and extremity changes (77.4 vs. 57.9%). Neurological symptoms (63.1 vs. 11.2%), kidney involvement (52.6 vs. 16.1%). Lymphocyte count (2.07 + 2.03 vs. 4.28 + 3.01/mm3), platelet count (197.89 + 187.51 vs. 420.37 + 200.08/mm3). KD vs. MIS-C types of Treatment: IVIG (96.8 vs. 94.7%), systemic steroids (4.82 vs. 94.7%), IVIG resistance (19.4 vs. 15.8). Finally, mortality in KD was 0% and 5.3% in MIS-C.
Conclusion: Significant differences such as severity of clinical presentation with multi-organ involvement and worst inflammatory response were found more frequently in MIS-C group than KD group, requiring more fluid replacement, use of inotropic agents and higher steroids dosages. Also, mortality rate was higher in patients with MIS-C than patients with KD.
Publisher
Colegio Mexicano de Inmunologia Clinica y Alergia, A. C.
Reference25 articles.
1. Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet. 2020;395(10237):1607‐1608. DOI:10.1016/S0140-6736(20)31094-1
2. Verdoni, L., Mazza, A., Gervasoni, A., Martelli, L., Ruggeri, M., Ciuffreda, M., … D’Antiga, L. (2020). An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. The Lancet. DOI:10.1016/s0140-6736(20)31103-x
3. World Health Organization. Multisystem inflammatory syndrome in children and adolescents temporally related to COVID-19. Available from: https://www.who.int/news- room/commentaries/detail/multisystem- inflammatory- syndrome- in- children- and- adolescents- with- covid- 19.
4. US Centers for Disease Control and Prevention. Multisystem inflammatory syndrome in children (MIS-C) associated with coronavirus disease 2019 (COVID-19) [Internet]. 2020. Available from:) https://emergency.cdc.gov/han/ 2020/han00432.asp.
5. Whittaker E, Bamford A, Kenny J, et al. Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2. JAMA. Published online June 08, 2020. DOI:10.1001/jama.2020.10369